supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago
drug:
Colestipol
supplement:
Niacin
Research Papers that Mention the Interaction
“The Cholesterol Lowering Atherosclerosis Study reported an increase in plasma homocyst(e)ine levels in patients receiving both colestipol and niacin compared with placebo.”
Niacin treatment increases plasma homocyst(e)ine levels.“BACKGROUND The Cholesterol Lowering Atherosclerosis Study, a controlled angiographic trial, has reported that new native coronary artery lesions are significantly reduced by aggressive blood lipid lowering therapy with colestipol plus niacin.”
“Specifically, CLAS was designed to determine whether combined therapy with colestipol plus niacin will produce clinically significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions.”
“In contrast, serum cholesterol levels fell 45 per cent when colestipol as combined with niacin.”
“In the Cholesterol Lowering Atherosclerosis Study using colestipol plus nicotinic acid , it was demonstrated by quantitative coronary angiography that coronary artery plaque regression is achievable with statistical significance.”
“The Cholesterol-Lowering Atherosclerosis Study demonstrated that combined therapy with a resin colestipol ) and nicotinic acid can reduce the progression of coronary atherosclerosis and the development of graft lesions in patients who have undergone coronary artery bypass graft surgery.”
“As prescribing of extended-release niacin increased, prescribing of colestipol , gemfibrozil, and probucol declined.”
“When used as single agents, the bile-acid sequestrants, cholestyramine and colestipol , lower LDL cholesterol concentrations by 20% to 35% in compliant patients, whereas decreases of 20% to 30% can be achieved with nicotinic acid in doses of 3 to 6 g/day.”
“The socalled Cholesterol Lowering Atherosclerosis Study" was a randomized, placebo-controlled trial in which lipoprotein concentrations were altered markedly with combined treatment with colestipol and nicotinic acid.”
“Plasma concentrations of LDL cholesterol declined 24% on colestipol ; the subsequent addition of nicotinic acid resulted in a further 31% fall so that values on the combined drug regimen were 47% below those seen on diet alone.”
“Treatment resulted in significant decreases in the LDL:HDL ratio which fell from 8.4 on diet to 3.3 on the colestipol plus nicotinic acid regimen.”
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback